CLL
Roche’s blood cancer drug gains EU approval
July 29, 2014Research and Development, Sales and Marketing CLL, Cancer, Gilead, Janssen, Roche
The European Commission has approved Roche’s new leukaemia drug Gazyvaro (obinutuzumab) as competition for the blood cancer market heats up. …
EMA approvals for rival blood cancer drugs
July 27, 2014Research and Development, Sales and Marketing CLL, Gilead, Janssen, chronic lymphocytic leukaemia, imbruvica, zydelig
Gilead and Janssen are set to face off in Europe after the CHMP recommended both of their rival blood cancer …
AbbVie ‘pleased’ with first year
February 3, 2014Sales and Marketing AbbVie, Abbott, CLL, EMA, HIV, Humira
Rheumatoid arthritis treatment Humira – as expected – has driven AbbVie in its first year as a standalone company, accounting …
US regulator ponders Arzerra
October 22, 2013Sales and Marketing Arzerra, CLL, FDA, GSK
GlaxoSmithKline and Genmab have submitted their blood cancer drug Arzerra to the FDA as a first-line treatment for chronic lymphocytic …
Novartis signs Regenerex deal
September 9, 2013Sales and Marketing CLL, Novartis, kidney, regenerex
Novartis has signed a deal with US biopharma firm Regenerex to use its novel stem cell-based platform, which may have …
Roche leukaemia drug granted speedy US review
July 3, 2013Research and Development, Sales and Marketing CLL, FDA, Roche, leukaemia, obinutuzumab
Roche’s investigational leukaemia drug could be available for US patients by the end of the year as the FDA looks …
MabThera shows improved leukaemia survival benefits
December 14, 2009Sales and Marketing CLL, MabThera, Roche
MabThera/Rituxan is the first treatment to show improved survival in previously untreated patients with chronic lymphocytic leukaemia (CLL), according to …
Latest content
Five Facts about cardiovascular disease
